|
Delayed
Sao Paulo
19:21:25 18/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 86.64 BRL | -85.05% |
|
+1.69% | +10.74% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Evolution of the Average Target: Vertex Pharmaceuticals Incorporated
Evolution of the Target Price: Vertex Pharmaceuticals Incorporated
Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +10.8% | |||||
| +3.86% | |||||
| +10.42% | |||||
| +3.99% | |||||
| +1.19% | |||||
| +35.21% | |||||
| -7.7% | |||||
| +7.29% | |||||
| +13.31% | |||||
| Average | +8.71% | |||||
| Weighted average by Cap. | +8.51% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Jefferies & Co. | |
| Daiwa Securities | |
| Rothschild & Co Redburn | |
| Canaccord Genuity | |
| TD Cowen | |
| Cantor Fitzgerald | |
| Stifel Nicolaus | |
| Goldman Sachs | |
| Barclays | |
| RBC Capital Markets | |
| Morgan Stanley | |
| UBS | |
| Baird | |
| Bernstein | |
| Evercore ISI | |
| Wells Fargo Securities | |
| Argus | |
| Maxim | |
| Truist Securities | |
| HC Wainwright | |
| Citigroup | |
| BMO Capital | |
| Oppenheimer | |
| Scotiabank | |
| Wolfe Research | |
| Leerink Partners | |
| JPMorgan Chase | |
| DBS Bank | |
| Guggenheim | |
| Redburn Atlantic | |
| Piper Sandler | |
| BofA Securities | |
| SVB Securities LLC | |
| Cowen | |
| SVB Leerink | |
| Raymond James | |
| Credit Suisse |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
- VRTX34 Stock
- Consensus Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
